Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease

Disease recurrence after allogeneic hematopoietic cell transplant (alloHCT) remains common, making improvements in conditioning regimens desirable. A dose-response relationship between busulfan exposure and outcome is known. Using individual real-time monitoring of the busulfan area under the curve...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Leuk Lymphoma
Prif Awduron: O’DONNELL, PETER H., ARTZ, ANDREW S., UNDEVIA, SAMIR D., PAI, RISH K., CERRO, PAULA DEL, HOROWITZ, SARAH, GODLEY, LUCY A., HART, JOHN, INNOCENTI, FEDERICO, LARSON, RICHARD A., ODENIKE, OLATOYOSI M., STOCK, WENDY, VAN BESIEN, KOEN
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477684/
https://ncbi.nlm.nih.gov/pubmed/20919852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.520773
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg